Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia.
D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D001629:Bezafibrate; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003404:Creatinine / Q000097:blood; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006951:Hyperlipoproteinemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D014508:Urea / Q000097:blood
D000960:Hypolipidemic Agents; D008055:Lipids; D002995:Clofibric Acid; D014508:Urea; D002784:Cholesterol; D003404:Creatinine; D000469:Alkaline Phosphatase; D002994:Clofibrate; D001629:Bezafibrate